Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) released its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10), Zacks reports.

Anixa Biosciences Trading Up 1.1 %

ANIX stock traded up $0.03 during midday trading on Tuesday, hitting $2.66. The company's stock had a trading volume of 42,995 shares, compared to its average volume of 102,146. The firm's 50-day moving average is $2.78 and its 200-day moving average is $3.03. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The company has a market cap of $85.64 million, a PE ratio of -6.82 and a beta of 0.86.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar bought 43,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now owns 559,925 shares of the company's stock, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction dated Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 75,289 shares of company stock worth $177,021. Insiders own 25.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, February 18th. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Remove Ads

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.